|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-3-25
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Alemtuzumab is a humanised monoclonal antibody that depletes lymphocytes, causing long-term immunomodulation. In a 3-year, rater-blinded phase 2 study (the CAMMS223 study) in patients with relapsing-remitting multiple sclerosis (RRMS), alemtuzumab reduced relapse rate and the risk of sustained accumulation of disability compared with subcutaneous interferon beta-1a, and the mean expanded disability status scale (EDSS) score of the alemtuzumab cohort improved compared with baseline. Adverse events included infusion-associated reactions, predominantly mild to moderate infections, thyroid disorders, and immune thrombocytopenia. In this study, we further analysed the CAMMS223 data with the aim of determining whether demographic and baseline disease-related characteristics affect the beneficial effects of alemtuzumab. Additionally, we aimed to describe a new outcome measure in multiple sclerosis research: sustained reduction in disability.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-beta,
http://linkedlifedata.com/resource/pubmed/chemical/alemtuzumab,
http://linkedlifedata.com/resource/pubmed/chemical/interferon beta 1a
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1474-4465
|
|
pubmed:author |
pubmed-author:BassAnn Doan-DoAD,
pubmed-author:BrinarVesnaV,
pubmed-author:ColesAlasdair JAJ,
pubmed-author:CompstonD Alastair SDA,
pubmed-author:FoxEdwardE,
pubmed-author:GazdaSuzanne KSK,
pubmed-author:LakeStephen LSL,
pubmed-author:MargolinDavid HDH,
pubmed-author:MoranSusanS,
pubmed-author:PalmerJeffreyJ,
pubmed-author:SelmajKrzysztof WKW,
pubmed-author:SmithM SheltonMS,
pubmed-author:VladicAntonA,
pubmed-author:WynnDaniel RDR
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
338-48
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21397567-Adjuvants, Immunologic,
pubmed-meshheading:21397567-Adolescent,
pubmed-meshheading:21397567-Adult,
pubmed-meshheading:21397567-Antibodies, Monoclonal,
pubmed-meshheading:21397567-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21397567-Antibodies, Neoplasm,
pubmed-meshheading:21397567-Disease-Free Survival,
pubmed-meshheading:21397567-Female,
pubmed-meshheading:21397567-Humans,
pubmed-meshheading:21397567-Interferon-beta,
pubmed-meshheading:21397567-Kaplan-Meier Estimate,
pubmed-meshheading:21397567-Male,
pubmed-meshheading:21397567-Middle Aged,
pubmed-meshheading:21397567-Multiple Sclerosis, Relapsing-Remitting,
pubmed-meshheading:21397567-Single-Blind Method,
pubmed-meshheading:21397567-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
|
|
pubmed:affiliation |
Department of Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. ajc1020@medschl.cam.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
